17.90 USD
↗ 0.51 (2.93%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
19.85
↗ 1.95 (10.92%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
19.85
↗ 1.95 (10.92%)
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $17.90 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 26, 2026.
Open?$17.39
High?$18.38
Low?$17.38
Prev. Close?$17.39
Volume?5.8M
Avg. Volume?1.9M
VWAP?$17.84
Rel. Volume?3.01x
Bid / Ask
Bid?$15.22 × 100
Ask?$20.62 × 100
Spread?$5.40
Midpoint?$17.92
Valuation & Ratios
Market Cap?2.0B
Shares Out?103.1M
Float?86.3M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?3.11
EPS?-$2.75
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?97
Momentum?62
Short Sent.?19
Piotroski F-Score?1/9Weak
Altman Z-Score?4.78Safe
Confidence?51%Low
Short InterestVery High
Short % of Float?17.40%High
Short Interest?15.0M
Days to Cover?10.1
Free Float86.3M
Avg Daily Volume1.5M
Settlement Date2026-06-15
Financial Health
Current Ratio?15.15Strong
Quick Ratio?15.15Strong
Cash Ratio?3.40Strong
Debt/Equity?0.14Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.11FAIR▾
Peers100
S&P54
P/S?27.87HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-4.9CHEAP▾
S&P97
EV/Sales?26.61HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-47.7%WEAK▾
S&P3
ROA?-38.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-303824000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day